Department of Surgery, Baylor Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas.
Department of Obstetrics and Gynecology, Prisma Health, Columbia, South Carolina.
JAMA. 2024 Sep 10;332(10):817-824. doi: 10.1001/jama.2024.11679.
Uterus transplant in women with absolute uterine-factor infertility offers the possibility of carrying their own pregnancy.
To determine whether uterus transplant is feasible and safe and results in births of healthy infants.
DESIGN, SETTING, AND PARTICIPANTS: A case series including 20 participants with uterine-factor infertility and at least 1 functioning ovary who underwent uterus transplant in a large US tertiary care center between September 14, 2016, and August 23, 2019.
The uterus transplant (from 18 living donors and 2 deceased donors) was surgically placed in an orthotopic position with vascular anastomoses to the external iliac vessels. Participants received immunosuppression until the transplanted uterus was removed following 1 or 2 live births or after graft failure.
Uterus graft survival and subsequent live births.
Of 20 participants (median age, 30 years [range, 20-36]; 2 Asian, 1 Black, and 16 White), 14 (70%) had a successful uterus allograft; all 14 recipients gave birth to at least 1 live-born infant. Eleven of 20 recipients had at least 1 complication. Maternal and/or obstetrical complications occurred in 50% of the successful pregnancies, with the most common being gestational hypertension (2 [14%]), cervical insufficiency (2 [14%]), and preterm labor (2 [14%]). Among the 16 live-born infants, there were no congenital malformations. Four of 18 living donors had grade 3 complications.
Uterus transplant was technically feasible and was associated with a high live birth rate following successful graft survival. Adverse events were common, with medical and surgical risks affecting recipients as well as donors. Congenital abnormalities and developmental delays have not occurred to date in the live-born children.
ClinicalTrials.gov Identifier: NCT02656550.
对于患有绝对子宫因素不孕的女性,子宫移植为其自身妊娠提供了可能性。
确定子宫移植是否可行且安全,并能导致健康婴儿的出生。
设计、环境和参与者:一项病例系列研究,纳入了 2016 年 9 月 14 日至 2019 年 8 月 23 日期间在美国一家大型三级护理中心接受子宫移植的 20 名患有子宫因素不孕且至少有 1 个功能卵巢的患者。
将子宫(来自 18 名活体供体和 2 名已故供体)通过外科手术移植到一个与髂外血管吻合的正位位置。参与者接受免疫抑制治疗,直到移植的子宫在 1 次或 2 次活产或移植物失功后被取出。
子宫移植物的存活和随后的活产。
在 20 名参与者中(中位年龄 30 岁[范围 20-36 岁];2 名亚洲人,1 名黑人,16 名白人),14 名(70%)成功进行了子宫同种异体移植;所有 14 名接受者均至少分娩了 1 名活产婴儿。20 名接受者中有 11 名至少发生了 1 次并发症。在成功妊娠中,母婴和/或产科并发症的发生率为 50%,最常见的是妊娠期高血压(2[14%])、宫颈功能不全(2[14%])和早产(2[14%])。在 16 名活产婴儿中,没有先天性畸形。18 名活体供体中有 4 名出现 3 级并发症。
子宫移植在技术上是可行的,在成功的移植物存活后,活产率很高。不良事件很常见,供体和受体都存在医疗和手术风险。迄今为止,在活产的儿童中没有发生先天性异常和发育迟缓。
ClinicalTrials.gov 标识符:NCT02656550。